COLL - Collegium Pharma's Xtampza ER growth expounds FY2021 outlook

Collegium Pharmaceutical (COLL) provides its FY2021 guidance as follows:Xtampza ER revenues expected to be in the range of $155-$165MNucynta franchise revenues in the range of $175-$185M.Adj. EBITDA (excluding stock-based compensation) is expected in the range of $160-$170M.Total operating expenses to range between $125M and $135M."Our 2021 revenue outlook is supported by Xtampza ER growth, stable profit contribution from the Nucynta franchise and a commitment to leverage our cost structure. This year, we expect to generate significant cash flow from operations," says EVP and CFO Paul Brannelly.FY2021 revenue consensus is $344.85M, which will mark the year-over-year growth of 10.63%. Source: Press ReleaseNow Read: BioMarin and Sarepta in the spotlight ahead of key trial results

For further details see:

Collegium Pharma's Xtampza ER growth expounds FY2021 outlook